Sorrento Therapeutics, Inc.
SRNE
SRNE was delisted on the 22nd of February, 2023.
94 hedge funds and large institutions have $209M invested in Sorrento Therapeutics, Inc. in 2018 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 22 increasing their positions, 13 reducing their positions, and 26 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
81% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 26
73% more capital invested
Capital invested by funds: $121M → $209M (+$88.5M)
69% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 13
29% more funds holding
Funds holding: 73 → 94 (+21)
47% less call options, than puts
Call options by funds: $3.77M | Put options by funds: $7.05M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$26.2M |
| 2 |
State Street
Boston,
Massachusetts
|
+$14.1M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.95M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$5.77M |
| 5 |
Morgan Stanley
New York
|
+$2.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$7.96M |
| 2 |
Man Group
London,
United Kingdom
|
-$6.91M |
| 3 |
IP
Intellectus Partners
San Francisco,
California
|
-$5.42M |
| 4 |
Renaissance Technologies
New York
|
-$3.71M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$3.21M |
SRNE Hedge Fund Activity: Q2 2018 in Review
94 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Sorrento Therapeutics, Inc. (SRNE) for Q2 2018, worth a combined $209M — up 73% from $121M a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new SRNE positions and 26 closed out — a net gain of 21 holders — while 22 added to existing stakes and 13 trimmed.
The largest buyer was BlackRock, adding an estimated $26.2M. The largest seller was Millennium Management, cutting an estimated $7.96M.
- 94 institutional investors held Sorrento Therapeutics, Inc. (SRNE) as of Q2 2018, up from 73 in Q1 2018.
- Funds reported $209M of Sorrento Therapeutics, Inc. stock for Q2 2018, up 73% quarter-over-quarter.
- 47 funds opened new Sorrento Therapeutics, Inc. positions in Q2 2018 and 26 closed out, a net change of +21 holders.
- The largest Sorrento Therapeutics, Inc. buyer in Q2 2018 was BlackRock, an estimated $26.2M added.
- The largest Sorrento Therapeutics, Inc. seller in Q2 2018 was Millennium Management, an estimated $7.96M sold.
Based on aggregated 13F filings for Q2 2018.